Jul 29 2009, 10:15 AM EST
GEN News Highlights
Recordati signed new marketing agreements for the benign prostatic hyperplasia (BPH) drug, silodosin, in Italy and South Africa. The deal with Nycomed’s Italian subsidiary covers the co-marketing of silodosin in Italy, and a separate agreement with Pharmaplan gives the South African company exclusive marketing and sales rights in South Africa.
For the South African market, Pharmaplan will also be responsible for filing an NDA to the country’s regulatory authorities. An MAA for silodosin was submitted to the EMEA in November 2008 and a decision is expected during the first half of 2010.
Pharmaplan is already Recordati’s South African licensee for the drugs Zanidip® (hypertension), Zaneril® (hypertension), and Lomexin® (vulvovaginal candidiasis).
Silodosin is an alpha-1 adrenergic receptor antagonist, indicated for the symptomatic treatment of BPH. The drug was originally developed by Kissei in Japan, where it has been marketed as Urief® since 2006. Recordati licensed the drug for Europe and a number of countries in the Middle East and Africa.
Silodosin was developed in North America by Watson Pharmaceuticals and was approved by the FDA in October 2008. Watson launched the drug as Rapaflo™ in April.
♦♦♦
Related News
Nycomed’s Intranasal Fentanyl Drug Gains European Approval for Breakthrough Cancer Pain (July 24, 2009)
Almirall to Commercialize Recordati's BPH Drug in Spain (Apr. 3, 2009)
Micromet Nets $2M Milestone Payment from Nycomed with Filing of Clinical Trial Application (Apr. 2, 2009)
Sanofi-Aventis to Commercialize AEterna Zentaris’ Late-Stage BPH Drug in the U.S. (Mar. 6, 2009)
NNE Acquires Germany-based Pharmaplan (Dec. 19, 2006)
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More GEN News Highlights
Listen
Save
Comment
View All